{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:21:02Z","timestamp":1783426862163,"version":"3.54.6"},"reference-count":35,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Schol Ed)"],"abstract":"<jats:p>Background: Hypertrophic cardiomyopathy (HCM) is genetically heterogeneous and characterized by left ventricular hypertrophy, myocardial fibrosis, and diverse clinical manifestations. Although circulating microRNAs (miRNAs) are promising biomarkers of pathological cardiac remodeling, the correlation of these miRNAs with specific clinical characteristics of HCM remains unclear. Therefore, we systematically reviewed and quantified the correlation between circulating miRNAs and structural and functional cardiac parameters in HCM. Methods: This systematic review and meta-analysis of observational studies evaluated the association between circulating miRNA expression levels and Echocardiography, magnetic resonance imaging, and histological parameters for HCM. We comprehensively searched the PubMed, Embase, Scopus, and Web of Science databases, and extracted and transformed correlation coefficients into Fisher\u2019s Z-scores. The study was registered with PROSPERO under registration number CRD420251058653. Meta-analyses were conducted using random-effects models, and heterogeneity was assessed using the I2 statistic. Sensitivity analyses, meta-regression, and publication bias were also assessed. Results: A total of 11 studies comprising 633 patients were included. Pooled analysis showed moderate-to-strong positive correlations between miRNAs (miR-21, miR-29a, miR-199a-5p, and miR-27a) and myocardial fibrosis, wall thickness, and left ventricular mass (r = 0.53; 95% confidence interval 0.40\u20130.64; I2 = 60.1%). Sensitivity and meta-regression analyses confirmed the robustness of the results, with no significant publication bias. The risk-of-bias assessment (Quality Assessment of Diagnostic Accuracy Studies 2) revealed moderate concerns, primarily related to patient selection and index-test blinding. Conclusion: Circulating miRNAs were significantly correlated with structural and functional cardiac changes in HCM, supporting the potential role of these miRNAs as noninvasive biomarkers. However, further high-quality studies are needed to validate their clinical applicability.<\/jats:p>","DOI":"10.31083\/fbs47633","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:05:49Z","timestamp":1783425949000},"source":"Crossref","is-referenced-by-count":0,"title":["Circulating MicroRNAs and Clinical Parameters in Hypertrophic Cardiomyopathy: A Systematic Review and Correlation Meta-Analysis"],"prefix":"10.31083","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-5206","authenticated-orcid":true,"given":"Antonio da Silva","family":"Menezes Junior","sequence":"first","affiliation":[{"name":"Department of Medicine, Federal University of Goi\u00e1s, Goi\u00e2nia, GO 74605-050, Brazil"},{"name":"Medical Department, Medical Sciences and Life School, Pontifical Catholic University of Goi\u00e1s, Goi\u00e2nia, GO 74605-050, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6787-7299","authenticated-orcid":true,"given":"Henrique Lima","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Federal University of Goi\u00e1s, Goi\u00e2nia, GO 74605-050, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3596-5643","authenticated-orcid":true,"given":"Khissya Beatryz Alves","family":"de Lima","sequence":"additional","affiliation":[{"name":"Department of Medicine, Federal University of Goi\u00e1s, Goi\u00e2nia, GO 74605-050, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Sun Y, Xiao Z, Chen Y, Xu D, Chen S. Susceptibility Modules and Genes in Hypertrophic Cardiomyopathy by WGCNA and ceRNA Network Analysis. Frontiers in Cell and Developmental Biology. 2022; 9: 822465.","DOI":"10.3389\/fcell.2021.822465"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Sons\u00f6z MR, Yilmaz M, Cevik E, Orta H, Bilge AK, Elitok A, et al. Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters. Heart, Lung & Circulation. 2022; 31: 199\u2013206.","DOI":"10.1016\/j.hlc.2021.04.019"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Foglieni C, Lombardi M, Lazzeroni D, Zerboni R, Lazzarini E, Bertoli G, et al. Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy. Biomedicines. 2022; 10: 2180.","DOI":"10.3390\/biomedicines10092180"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kuster DWD, Mulders J, Ten Cate FJ, Michels M, Dos Remedios CG, da Costa Martins PA, et al. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. Journal of Molecular and Cellular Cardiology. 2013; 65: 59\u201366.","DOI":"10.1016\/j.yjmcc.2013.09.012"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Menezes Junior ADS, Fran\u00e7a-E-Silva ALGD, Oliveira HLD, Lima KBAD, Porto IDOP, Pedroso TMA, et al. Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review. International Journal of Molecular Sciences. 2024; 25: 5855.","DOI":"10.3390\/ijms25115855"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Tao L, Bei Y, Chen P, Lei Z, Fu S, Zhang H, et al. Crucial Role of miR-433 in Regulating Cardiac Fibrosis. Theranostics. 2016; 6: 2068\u20132083.","DOI":"10.7150\/thno.15007"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Lin X, Steinberg S, Kandasamy SK, Afzal J, Mbiyangandu B, Liao SE, et al. Common miR-590 variant rs6971711 present only in African Americans reduces miR-590 biogenesis. PLoS One. 2016; 11: e0156065.","DOI":"10.1371\/journal.pone.0156065"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Towe EC, Bos JM, Ommen SR, Gersh BJ, Ackerman MJ. Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy. Congenital Heart Disease. 2015; 10: E139\u2013E145.","DOI":"10.1111\/chd.12242"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Gong K, Yang K, Xie T, Luo Y, Guo H, Tan Z, et al. Identification of circRNA-miRNA-mRNA regulatory network and its role in cardiac hypertrophy. PloS One. 2023; 18: e0279638.","DOI":"10.1371\/journal.pone.0279638"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research Ed.). 2021; 372: n71.","DOI":"10.1136\/bmj.n71"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Igelstr\u00f6m E, Campbell M, Craig P, Katikireddi SV. Cochrane\u2019s risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: A methodological systematic review. Journal of Clinical Epidemiology. 2021; 140: 22\u201332.","DOI":"10.1016\/j.jclinepi.2021.08.022"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P, et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2014; 63: 920\u2013927.","DOI":"10.1016\/j.jacc.2013.09.041"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, et al. Blood-based microRNA signatures differentiate Thank you for bringing this to our attention. The reference has been carefully reviewed and remains appropriate for the scope of this manuscript.various forms of cardiac hypertrophy. International Journal of Cardiology. 2015; 196: 115\u2013122.","DOI":"10.1016\/j.ijcard.2015.05.185"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Li M, Chen X, Chen L, Chen K, Zhou J, Song J. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM. Journal of Translational Medicine. 2018; 16: 161.","DOI":"10.1186\/s12967-018-1534-3"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Thottakara T, Lund N, Kr\u00e4mer E, Kirchhof P, Carrier L, Patten M. A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy. Biomolecules. 2021; 11: 1718.","DOI":"10.3390\/biom11111718"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Zhang C, Zhang H, Zhao L, Wei Z, Lai Y, Ma X. Differential Expression of microRNAs in Hypertrophied Myocardium and Their Relationship to Late Gadolinium Enhancement, Left Ventricular Hypertrophy and Remodeling in Hypertrophic Cardiomyopathy. Diagnostics (Basel, Switzerland). 2022; 12: 1978.","DOI":"10.3390\/diagnostics12081978"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Gudkova AY, Davidova VG, Bezhanishvili TG, Pyko SA, Zarayskiy MI. Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathy. Terapevticheskii Arkhiv. 2020; 92: 51\u201356.","DOI":"10.26442\/00403660.2020.04.000272"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Huang D, Chen Z, Wang J, Chen Y, Liu D, Lin K. MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy. Bioscience Reports. 2020; 40: BSR20191234.","DOI":"10.1042\/BSR20191234"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Fang L, Ellims AH, Moore XL, White DA, Taylor AJ, Chin-Dusting J, et al. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. Journal of Translational Medicine. 2015; 13: 314.","DOI":"10.1186\/s12967-015-0672-0"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Davydova V, Bezhanishvili TG, Filatova ME, Andreeva SE, Streltsova AA, Poliakova AA, et al. Expression of miRNA-21 level in hypertrophic cardiomyopathy patients with chronic heart failure and preserved left ventricular ejection fraction: results of a 6-year follow-up. European Heart Journal. 2020; 41: ehaa946.2088.","DOI":"10.1093\/ehjci\/ehaa946.2088"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ntelios D, Meditskou S, Efthimiadis G, Pitsis A, Nikolakaki E, Girtovitis F, et al. Elevated plasma levels of miR-29a are associated with hemolysis in patients with hypertrophic cardiomyopathy. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2017; 471: 321\u2013326.","DOI":"10.1016\/j.cca.2017.07.004"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Garmany R, Bos JM, Dasari S, Tester D, dos Remedios C, Maleszewski J, et al. PO-02-142 MiRNA down-regulate hypertrophy and inflammatory pathways in the transcriptome of hypertrophic cardiomyopathy myectomy tissue. Heart Rhythm. 2023; 20: S262.","DOI":"10.1016\/j.hrthm.2023.03.714"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Osmak G, Baulina N, Kiselev I, Favorova O. MiRNA-Regulated Pathways for Hypertrophic Cardiomyopathy: Network-Based Approach to Insight into Pathogenesis. Genes. 2021; 12: 2016.","DOI":"10.3390\/genes12122016"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Lombardi M, Lazzeroni D, Benedetti G, Bertoli G, Lazarevic D, Riba M, et al. Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy. Clinical and Translational Medicine. 2021; 11: e435.","DOI":"10.1002\/ctm2.435"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Akdeniz M, Eryilmaz U, Akgullu C, Bozkurt G. The relationship of hypertrophic cardiomyopathy and micro-RNA\u2019s. Journal of Clinical and Analytical Medicine. 2017; 8: 482\u2013487.","DOI":"10.4328\/JCAM.5215"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Hernandez-Torres F, Aranega AE, Franco D. Identification of regulatory elements directing miR-23a-miR-27a-miR-24-2 transcriptional regulation in response to muscle hypertrophic stimuli. Biochimica et Biophysica Acta. 2014; 1839: 885\u2013897.","DOI":"10.1016\/j.bbagrm.2014.07.009"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Scolari FL, Faganello LS, Garbin HI, Piva E Mattos B, Biolo A. A systematic review of microRNAs in patients with hypertrophic cardiomyopathy. International Journal of Cardiology. 2021; 327: 146\u2013154.","DOI":"10.1016\/j.ijcard.2020.11.004"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Danielson LS, Park DS, Rotllan N, Chamorro-Jorganes A, Guijarro MV, Fernandez-Hernando C, et al. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2013; 27: 1460\u20131467.","DOI":"10.1096\/fj.12-221994"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Pisklova MV, Baulina NM, Kiselev IS, Zateyshchikov DA, Favorova OO, Chumakova OS. The levels of certain circulating microRNAs in hypertrophic cardiomyopathy are associated with echocardiographic parameters. Terapevticheskii Arkhiv. 2023; 95: 302\u2013308.","DOI":"10.26442\/00403660.2023.04.202162"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Sucharov CC, Neltner B, Pietra AE, Karimpour-Fard A, Patel J, Ho CY, et al. Circulating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic Cardiomyopathy. Circulation. Heart Failure. 2023; 16: e010291.","DOI":"10.1161\/CIRCHEARTFAILURE.122.010291"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Angelopoulos A, Oikonomou E, Vogiatzi G, Antonopoulos A, Tsalamandris S, Georgakopoulos C, et al. MicroRNAs as biomarkers in hypertrophic cardiomyopathy: current state of the art. Current Medicinal Chemistry. 2021; 28: 7400\u20137412.","DOI":"10.2174\/0929867328666210405122703"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Luo F, Liu W, Bu H. MicroRNAs in hypertrophic cardiomyopathy: pathogenesis, diagnosis, treatment potential and roles as clinical biomarkers. Heart Failure Reviews. 2022; 27: 2211\u20132221.","DOI":"10.1007\/s10741-022-10231-z"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Roma-Rodrigues C, Raposo LR, Fernandes AR. MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far. BioMed Research International. 2015; 2015: 983290.","DOI":"10.1155\/2015\/983290"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Carabetta N, Siracusa C, Leo I, Panuccio G, Strangio A, Sabatino J, et al. Cardiomyopathies: The Role of Non-Coding RNAs. Non-coding RNA. 2024; 10: 53.","DOI":"10.3390\/ncrna10060053"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Dai Y, Dai D, Mehta JL. MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker. Journal of the American College of Cardiology. 2014; 64: 2181.","DOI":"10.1016\/j.jacc.2014.03.064"}],"container-title":["Frontiers in Bioscience-Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/18\/2\/10.31083\/FBS47633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:06:15Z","timestamp":1783425975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/18\/2\/10.31083\/FBS47633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1945-0516(26)02977-0"],"URL":"https:\/\/doi.org\/10.31083\/fbs47633","relation":{},"ISSN":["1945-0516","1945-0524"],"issn-type":[{"value":"1945-0516","type":"print"},{"value":"1945-0524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"47633"}}